Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

76 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Broader Economic Value of Treatment for Diabetic Macular Edema.
Mulligan K, Kim J, Tysinger B, Blim J, Emerson G, Ferrone PJ, Kim JE, Seabury S, Hahn P. Mulligan K, et al. Among authors: ferrone pj. Diabetes Care. 2023 Jun 1;46(6):1196-1203. doi: 10.2337/dc22-2527. Diabetes Care. 2023. PMID: 37186032
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
Brown DM, Boyer DS, Do DV, Wykoff CC, Sakamoto T, Win P, Joshi S, Salehi-Had H, Seres A, Berliner AJ, Leal S, Vitti R, Chu KW, Reed K, Rao R, Cheng Y, Sun W, Voronca D, Bhore R, Schmidt-Ott U, Schmelter T, Schulze A, Zhang X, Hirshberg B, Yancopoulos GD, Sivaprasad S; PHOTON Investigators. Brown DM, et al. Lancet. 2024 Mar 23;403(10432):1153-1163. doi: 10.1016/S0140-6736(23)02577-1. Epub 2024 Mar 7. Lancet. 2024. PMID: 38461843 Clinical Trial.
Pegcetacoplan for the treatment of geographic atrophy secondary to age-related macular degeneration (OAKS and DERBY): two multicentre, randomised, double-masked, sham-controlled, phase 3 trials.
Heier JS, Lad EM, Holz FG, Rosenfeld PJ, Guymer RH, Boyer D, Grossi F, Baumal CR, Korobelnik JF, Slakter JS, Waheed NK, Metlapally R, Pearce I, Steinle N, Francone AA, Hu A, Lally DR, Deschatelets P, Francois C, Bliss C, Staurenghi G, Monés J, Singh RP, Ribeiro R, Wykoff CC; OAKS and DERBY study investigators. Heier JS, et al. Lancet. 2023 Oct 21;402(10411):1434-1448. doi: 10.1016/S0140-6736(23)01520-9. Lancet. 2023. PMID: 37865470 Clinical Trial.
Efficacy, durability, and safety of faricimab with extended dosing up to every 16 weeks in Japanese patients with diabetic macular edema: 1-year results from the Japan subgroup of the phase 3 YOSEMITE trial.
Shimura M, Kitano S, Ogata N, Mitamura Y, Oh H, Ochi H, Ohsawa S, Hirakata A; YOSEMITE and RHINE Investigators. Shimura M, et al. Jpn J Ophthalmol. 2023 May;67(3):264-279. doi: 10.1007/s10384-023-00979-8. Epub 2023 Mar 10. Jpn J Ophthalmol. 2023. PMID: 36897413 Free PMC article. Clinical Trial.
Ophthalmic Outcomes After Silicone Oil Removal.
Jiao G, Shah PP, Shakin EP, Lee JG, Ferrone PJ, Rhee DY, Romero JM, Rosenblatt BJ, Graham KB, Lin J. Jiao G, et al. Among authors: ferrone pj. J Vitreoretin Dis. 2024 Aug 15:24741264241271645. doi: 10.1177/24741264241271645. Online ahead of print. J Vitreoretin Dis. 2024. PMID: 39554621 Free PMC article.
Ophthalmologic Presentations of Incontinentia Pigmenti.
Rai RS, Li AS, Ferrone PJ. Rai RS, et al. Among authors: ferrone pj. J Vitreoretin Dis. 2024 Jan 28;8(2):186-191. doi: 10.1177/24741264241227680. eCollection 2024 Mar-Apr. J Vitreoretin Dis. 2024. PMID: 38465353
Opportunity Cost of Vitreoretinal Surgeries.
Leung EH, Patel S, Reddy R, Boucher N, Sharma C, Blim J, Ferrone PJ, Hahn P; American Society of Retina Specialists Health Economics Committee. Leung EH, et al. Among authors: ferrone pj. J Vitreoretin Dis. 2023 Jun 17;7(4):275-280. doi: 10.1177/24741264231178590. eCollection 2023 Jul-Aug. J Vitreoretin Dis. 2023. PMID: 37927325 Free PMC article.
76 results